Skip to main content
Vai all'homepage della Commissione europea (si apre in una nuova finestra)
italiano italiano
CORDIS - Risultati della ricerca dell’UE
CORDIS
Contenuto archiviato il 2024-06-17

Therapeutic recombinant allergens from structural allergology

Obiettivo

The network aims at generating recombinant allergens and modified recombinant allergens based on structural allergology for industrial production of test vaccines against Age-mediated allergy. Specific allergy vaccination (immunotherapy) is the only therapeutic treatment available that changes the natural course of the allergic disease and has the potential to be preventive. Today's vaccines are derived from natural source. Vaccines based on recombinant allergens will provide vaccines with increased safety profile and clinical efficacy.
In summary, the lack of recombinant Ves v 1 and Der p 1 has been major obstacles in the developing and testing of complete recombinant vaccins towards wasp and house-dust mites, respectively. Activities addressing this issue is continuing outside the TRAFSA project. The future recombinant active ingredient of a vaccine against cat allergy has been isolated and characterised, forming the basis for further pre-clinical work. Wasp venom vaccine. A complete recombinant wasp vaccine should consist of three components; Ves v 1, Ves v 2 and Ves v 5. Ves v 1. This protein has proven to be difficult to express in its recombinant form, hampering any immunochemical and/or biological charaterisation. Ves v 2. This component has been successfully expressed, purified and charaterised. The crystal structure was solved and human epitopes mapped. Ves v 5. This component was partially charaterised prior to the project and has been further tested and epitope mapped. An animal model for tolerance induction was developed within the project. Cat allergy vaccine.

The major component of a future recombinant cat vaccine, Fel d 1, has been successfully expressed and characterised. The recombinant molecule is indistinguishable from its natural counterpart in terms of structure and immunological activity. House-dust mite allergy vaccine. The recombinant vaccine should consist of two components; Der p 1 and Der p 2. Der p 1. This component has also shown to be difficult to express in the systems tried during the project, hampering a detailed characterisation of the molecule. Der p 2. This component has been sucessfully expressed and characterised. An analog, Der f 2, has been crystallised and its structure solved, revealing cross-reactive allergic epitopes shared between Der p 2 and Der f 2. Immune responses towards natural Der p 1 and Der p 2 have been studied in animal models and mutants of Der p 2 have been designed.

Campo scientifico (EuroSciVoc)

CORDIS classifica i progetti con EuroSciVoc, una tassonomia multilingue dei campi scientifici, attraverso un processo semi-automatico basato su tecniche NLP. Cfr.: Il Vocabolario Scientifico Europeo.

È necessario effettuare l’accesso o registrarsi per utilizzare questa funzione

Programma(i)

Programmi di finanziamento pluriennali che definiscono le priorità dell’UE in materia di ricerca e innovazione.

Argomento(i)

Gli inviti a presentare proposte sono suddivisi per argomenti. Un argomento definisce un’area o un tema specifico per il quale i candidati possono presentare proposte. La descrizione di un argomento comprende il suo ambito specifico e l’impatto previsto del progetto finanziato.

Invito a presentare proposte

Procedura per invitare i candidati a presentare proposte di progetti, con l’obiettivo di ricevere finanziamenti dall’UE.

Dati non disponibili

Meccanismo di finanziamento

Meccanismo di finanziamento (o «Tipo di azione») all’interno di un programma con caratteristiche comuni. Specifica: l’ambito di ciò che viene finanziato; il tasso di rimborso; i criteri di valutazione specifici per qualificarsi per il finanziamento; l’uso di forme semplificate di costi come gli importi forfettari.

CSC - Cost-sharing contracts

Coordinatore

ALK-ABELLO AS
Contributo UE
Nessun dato
Indirizzo
Boge Alle 6-8
2970 HOERSHOLM
Danimarca

Mostra sulla mappa

Costo totale

I costi totali sostenuti dall’organizzazione per partecipare al progetto, compresi i costi diretti e indiretti. Questo importo è un sottoinsieme del bilancio complessivo del progetto.

Nessun dato

Partecipanti (4)

Il mio fascicolo 0 0